This report describes and explains the pancreatic cancer drugs market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.
The global pancreatic cancer drugs market reached a value of nearly $3,872.5 million in 2022, having increased at a compound annual growth rate (CAGR) of 6.5% since 2017. The market is expected to grow from $3,872.5 million in 2022 to $5,519.4 million in 2027 at a rate of 7.3%. The market is then expected to grow at a CAGR of 6.9% from 2027 and reach $7,720.1 million in 2032.
Growth in the historic period resulted from strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer. Factors that negatively affected growth in the historic period were the high cost of drugs, low healthcare access in developing countries and the coronavirus pandemic.
Going forward, an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support will drive the market. Factors that could hinder the growth of the pancreatic cancer drugs market in the future include a rise in interest rates and the Russia- Ukraine war.
The pancreatic cancer drugs market is segmented by type into pancreatic neuroendocrine cancer drugs and pancreatic exocrine cancer drugs. The pancreatic neuroendocrine cancer drugs was the largest segment of the pancreatic cancer drugs market by type, accounting for $3,698.9 million or 95.5% of the total market in 2022. The pancreatic exocrine cancer drugs market is expected to be the fastest-growing segment going forward at a CAGR of 7.7%.
The pancreatic cancer drugs market is segmented by end-users into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies market was the largest segment of the pancreatic cancer drugs market by end-users, accounting for $1,955.9 million or 50.5% of the total market in 2022. The retail pharmacies market is expected to be the fastest-growing segment going forward at a CAGR of 7.5%.
The pancreatic cancer drugs market is segmented by drug combination into single, double, triplet and quadruplet. The double was the largest segment of the pancreatic cancer drugs market by drug combination, accounting for $2,457.6 million or 63.5% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 7.8%.
North America was the largest region in the pancreatic cancer drugs market, accounting for 40.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the pancreatic cancer drugs market will be the Middle East and South America, where growth will be at CAGRs of 13.5% and 10.8% respectively from 2022-2027.
The global pancreatic cancer drugs market is concentrated, with a large number of small players. The top ten competitors in the market made up to 61.17% of the total market in 2021. Bristol-Myers Squibb Company was the largest competitor with 11.94% share of the market, followed by Pfizer Inc. with 10.69%, AstraZeneca PLC with 10.17%, F. Hoffmann-La Roche AG with 9.07%, Novartis AG with 7.20%, Abbvie Inc. with 5.16%, Merck & Co., Inc. with 2.86%, Teva Pharmaceutical Industries with 2.00%, Amgen Incorporation with 1.42% and Eli Lilly and Company with 0.67%.
The top opportunities in the pancreatic cancer drugs market by type will arise in the pancreatic neuroendocrine cancer drugs market, which will gain $1,568.8 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by end-users will arise in the hospital pharmacies market, which will gain $812.5 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by drug combination will arise in the double market, which will gain $1,121.4 million of global annual sales by 2027. The pancreatic cancer drugs market size will gain the most in the USA at $461.5 million.
Market-trend-based strategies for the pancreatic cancer drugs market include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.
Player-adopted strategies in the pancreatic cancer drugs industry include enhancing business capabilities through strategic partnership and collaborations, focusing on providing targeted treatment options for pancreatic cancer patients through receiving regulatory approvals, strengthening business capabilities through partnerships and collaborations and enhancing business operations through securing regulatory approvals.
To take advantage of the opportunities, the publisher recommends the pancreatic cancer drugs companies to focus on development of new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment for pancreatic cancer treatment, focus on product innovations, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, continue to target fast-growing end-users.
The global pancreatic cancer drugs market reached a value of nearly $3,872.5 million in 2022, having increased at a compound annual growth rate (CAGR) of 6.5% since 2017. The market is expected to grow from $3,872.5 million in 2022 to $5,519.4 million in 2027 at a rate of 7.3%. The market is then expected to grow at a CAGR of 6.9% from 2027 and reach $7,720.1 million in 2032.
Growth in the historic period resulted from strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer. Factors that negatively affected growth in the historic period were the high cost of drugs, low healthcare access in developing countries and the coronavirus pandemic.
Going forward, an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support will drive the market. Factors that could hinder the growth of the pancreatic cancer drugs market in the future include a rise in interest rates and the Russia- Ukraine war.
The pancreatic cancer drugs market is segmented by type into pancreatic neuroendocrine cancer drugs and pancreatic exocrine cancer drugs. The pancreatic neuroendocrine cancer drugs was the largest segment of the pancreatic cancer drugs market by type, accounting for $3,698.9 million or 95.5% of the total market in 2022. The pancreatic exocrine cancer drugs market is expected to be the fastest-growing segment going forward at a CAGR of 7.7%.
The pancreatic cancer drugs market is segmented by end-users into hospital pharmacies, retail pharmacies and other end-users. The hospital pharmacies market was the largest segment of the pancreatic cancer drugs market by end-users, accounting for $1,955.9 million or 50.5% of the total market in 2022. The retail pharmacies market is expected to be the fastest-growing segment going forward at a CAGR of 7.5%.
The pancreatic cancer drugs market is segmented by drug combination into single, double, triplet and quadruplet. The double was the largest segment of the pancreatic cancer drugs market by drug combination, accounting for $2,457.6 million or 63.5% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 7.8%.
North America was the largest region in the pancreatic cancer drugs market, accounting for 40.7% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the pancreatic cancer drugs market will be the Middle East and South America, where growth will be at CAGRs of 13.5% and 10.8% respectively from 2022-2027.
The global pancreatic cancer drugs market is concentrated, with a large number of small players. The top ten competitors in the market made up to 61.17% of the total market in 2021. Bristol-Myers Squibb Company was the largest competitor with 11.94% share of the market, followed by Pfizer Inc. with 10.69%, AstraZeneca PLC with 10.17%, F. Hoffmann-La Roche AG with 9.07%, Novartis AG with 7.20%, Abbvie Inc. with 5.16%, Merck & Co., Inc. with 2.86%, Teva Pharmaceutical Industries with 2.00%, Amgen Incorporation with 1.42% and Eli Lilly and Company with 0.67%.
The top opportunities in the pancreatic cancer drugs market by type will arise in the pancreatic neuroendocrine cancer drugs market, which will gain $1,568.8 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by end-users will arise in the hospital pharmacies market, which will gain $812.5 million of global annual sales by 2027. The top growth potential in the pancreatic cancer drugs market by drug combination will arise in the double market, which will gain $1,121.4 million of global annual sales by 2027. The pancreatic cancer drugs market size will gain the most in the USA at $461.5 million.
Market-trend-based strategies for the pancreatic cancer drugs market include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.
Player-adopted strategies in the pancreatic cancer drugs industry include enhancing business capabilities through strategic partnership and collaborations, focusing on providing targeted treatment options for pancreatic cancer patients through receiving regulatory approvals, strengthening business capabilities through partnerships and collaborations and enhancing business operations through securing regulatory approvals.
To take advantage of the opportunities, the publisher recommends the pancreatic cancer drugs companies to focus on development of new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment for pancreatic cancer treatment, focus on product innovations, expand in emerging markets, continue to focus on developed markets, focus on strategic collaborations, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, continue to target fast-growing end-users.
Table of Contents
1. Executive Summary2. Table Of Contents3. List Of Figures4. List Of Tables5. Report Structure19. Pipeline Analysis
6. Introduction And Market Characteristics
7. Major Market Trends
8. Global Market Size and Growth
9. Global Pancreatic Cancer Drugs Market Segmentation
10. Pancreatic Cancer Drugs Market, Regional and Country Analysis
11. Asia-Pacific Market
12. Western Europe Market
13. Eastern Europe Market
14. North America Market
15. South America Market
16. Middle East Market
17. Africa Market
18. Competitive Landscape and Company Profiles
20. Key Mergers And Acquisitions
21. Opportunities And Strategies
22. Pancreatic Cancer Drugs Market, Conclusions And Recommendations
23. Appendix
Executive Summary
Pancreatic Cancer Drugs Global Market Opportunities and Strategies to 2032 provides the strategists; marketers and senior management with the critical information they need to assess the global Pancreatic cancer drugs market as it emerges from the COVID 19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Description:
Where is the largest and fastest-growing market for pancreatic cancer drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The Pancreatic cancer drugs market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider pancreatic cancer drugs market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics
- Key Trends
- Global Market Type and Growth
- Regional Analysis
- Market Segmentation
- Regional Market Type and Growth
- Competitive Landscape
- Key Mergers and Acquisitions
- Opportunities and Strategies -
- Conclusions and Recommendations -
- Appendix -
Scope
Markets Covered:
1) By Type: Pancreatic Neuroendocrine Cancer Drugs; Pancreatic Exocrine Cancer Drugs2) By Drug Combination: Single; Double; Triplet; Quadruplet
3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
Companies Mentioned: Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; Novartis AG
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; pancreatic cancer drugs indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Bristol-Myers Squibb Company
- Pfizer Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche AG
- Novartis AG
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 295 |
Published | April 2023 |
Forecast Period | 2021 - 2031 |
Estimated Market Value ( USD | $ 3872.5 Million |
Forecasted Market Value ( USD | $ 7720.1 Million |
Compound Annual Growth Rate | 7.1% |
Regions Covered | Global |
No. of Companies Mentioned | 5 |